Who is sponsoring REDUCE CMD?

REDUCE CMD is sponsored by UMC Utrecht.

What condition does REDUCE CMD study?

REDUCE CMD studies Angina (Stable), Coronary Microvascular Disease.

What drugs are being tested in REDUCE CMD?

Interventions: Coronary sinus reducer, Sham CSR procedure.

What is the status of REDUCE CMD?

REDUCE CMD is currently ENROLLING_BY_INVITATION.

Last reviewed 2025-12-04 · How we verify

Coronary Sinus Reducer in Coronary Microvascular Disease (REDUCE CMD)

NCT06898541 NA ENROLLING_BY_INVITATION

Coronary microvascular dysfunction (CMD) is a common cause of treatment- resistant angina that lacks evidence-based treatment options. The coronary sinus reducer (CSR) is an hourglass-shaped stainless steel mesh, designed to create a controlled narrowing of the coronary sinus (CS). By augmenting CS pressure, CSR implantation was shown to improve myocardial perfusion, potentially providing a novel treatment for patients with CMD. REDUCE CMD is a placebo-controlled study of CSR in 50 patients with CMD. The main study endpoints are the change in coronary flow reserve from baseline to 6 months in the CSR-arm versus the placebo arm, and the difference in number of daily episodes of angina recorded on the ORBITA-app at 6 month follow-up in the CSR-arm versus the placebo arm.

Details

Lead sponsor	UMC Utrecht
Phase	NA
Status	ENROLLING_BY_INVITATION
Enrolment	50
Start date	Thu Nov 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Nov 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Angina (Stable)
Coronary Microvascular Disease

Interventions

Coronary sinus reducer
Sham CSR procedure

Countries

Netherlands